10
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Trends in Racial and Ethnic Disparities in the Receipt of Lifesaving Procedures for Hospitalized Patients With Decompensated Cirrhosis in the US, 2009-2018

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Key Points

          Question

          What are the trends in receipt of procedures for hospitalized patients with decompensated cirrhosis by race and ethnicity in the United States?

          Findings

          In this cross-sectional study 717 580 admissions for decompensated cirrhosis, there were no racial disparities in receipt of upper endoscopy for variceal hemorrhage by 2018; however, compared with White patients, Black patients remained less likely to receive transjugular portosystemic shunt for variceal hemorrhage and ascites. In 2018, both Black and Hispanic patients remained less likely to receive liver transplant, and Black patients had higher odds of death.

          Meaning

          These findings suggest that racial and ethnic disparities in receipt of complex life-saving procedures and in mortality in the US persisted over time.

          Abstract

          This cross-sectional study evaluates trends in receipt of procedures to treat decompensated cirrhosis by race and ethnicity from 2009 to 2018 in the US.

          Abstract

          Importance

          Patients with decompensated cirrhosis are hospitalized for acute management with temporizing and lifesaving procedures. Published data to inform intervention development in this area are more than a decade old, and it is not clear whether there have been improvements in disparities in the receipt of these procedures over time.

          Objective

          To evaluate the associations of race and ethnicity with receipt of procedures to treat decompensated cirrhosis over time in the US.

          Design, Setting, and Participants

          This retrospective cross-sectional study analyzed National Inpatient Sample data on cirrhosis admissions among patients with portal hypertension–related complications from 2009 to 2018. All hospital discharges for individuals aged 18 years and older from 2009 to 2018 were assessed for inclusion. Admissions were included if they contained at least 1 cirrhosis-related International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) or International Statistical Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) code and at least 1 cirrhosis-related complication ICD-9-CM or ICD-10-CM code (ie, ascites, hepatic encephalopathy, variceal hemorrhage [VH], and hepatorenal syndrome [HRS]). Data were analyzed from January to June 2022.

          Exposure

          Hospitalization for decompensated cirrhosis.

          Main Outcomes and Measures

          The outcomes of interest were trends in the odds ratios (ORs) for receiving procedures (upper endoscopy, transjugular portosystemic shunt [TIPS], hemodialysis, and liver transplantation [LT]) for decompensated cirrhosis and mortality by race and ethnicity, modeled over time. Multivariable logistic regression was used to assess these outcomes.

          Results

          Among 717 580 admissions (median [IQR] age, 58 [52-67] years), 345 644 patients (9.8%) were Black, 623 991 patients (17.6%) were Hispanic, and 2 340 031 patients (47.4%) were White. Based on the modeled trends, by 2018, there were no significant differences by race or ethnicity in the odds of receiving upper endoscopy for VH. However, Black patients remained less likely than White patients to undergo TIPS for VH (OR, 0.54; 95% CI, 0.47-0.62) and ascites (OR, 0.34; 95% CI, 0.31-0.38). The disparity in receipt of LT improved for Black and Hispanic patients over the study period; however, by 2018, both groups remained less likely to undergo LT than their White counterparts (Black: OR, 0.66; 95% CI, 0.61-0.70; Hispanic: OR, 0.74; 95% CI, 0.70-0.78). The odds of death in Black and Hispanic patients declined over the study period but remained higher in Black patients than White patients in 2018 (OR, 1.08; 95% CI, 1.05-1.11).

          Conclusions and Relevance

          In this cross-sectional study of individuals hospitalized with decompensated cirrhosis, there were racial and ethnic disparities in receipt of complex lifesaving procedures and in mortality that persisted over time.

          Related collections

          Most cited references32

          • Record: found
          • Abstract: found
          • Article: not found

          NASH Leading Cause of Liver Transplant in Women: Updated Analysis of Indications For Liver Transplant and Ethnic and Gender Variances

          Chronic infection with hepatitis C virus (HCV) was previously the leading indication for liver transplant (LT) in the United States. However, since 2014 the use of direct-acting antivirals (DAAs) has decreased the chronic HCV burden, while the prevalence of nonalcoholic steatohepatitis (NASH) has risen substantially through the last decade. Both gender and ethnic disparities in indications for LT have been shown in the past but no data on this have been reported since the implementation of DAAs.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Early use of TIPS in patients with cirrhosis and variceal bleeding.

            Patients with cirrhosis in Child-Pugh class C or those in class B who have persistent bleeding at endoscopy are at high risk for treatment failure and a poor prognosis, even if they have undergone rescue treatment with a transjugular intrahepatic portosystemic shunt (TIPS). This study evaluated the earlier use of TIPS in such patients. We randomly assigned, within 24 hours after admission, a total of 63 patients with cirrhosis and acute variceal bleeding who had been treated with vasoactive drugs plus endoscopic therapy to treatment with a polytetrafluoroethylene-covered stent within 72 hours after randomization (early-TIPS group, 32 patients) or continuation of vasoactive-drug therapy, followed after 3 to 5 days by treatment with propranolol or nadolol and long-term endoscopic band ligation (EBL), with insertion of a TIPS if needed as rescue therapy (pharmacotherapy-EBL group, 31 patients). During a median follow-up of 16 months, rebleeding or failure to control bleeding occurred in 14 patients in the pharmacotherapy-EBL group as compared with 1 patient in the early-TIPS group (P=0.001). The 1-year actuarial probability of remaining free of this composite end point was 50% in the pharmacotherapy-EBL group versus 97% in the early-TIPS group (P<0.001). Sixteen patients died (12 in the pharmacotherapy-EBL group and 4 in the early-TIPS group, P=0.01). The 1-year actuarial survival was 61% in the pharmacotherapy-EBL group versus 86% in the early-TIPS group (P<0.001). Seven patients in the pharmacotherapy-EBL group received TIPS as rescue therapy, but four died. The number of days in the intensive care unit and the percentage of time in the hospital during follow-up were significantly higher in the pharmacotherapy-EBL group than in the early-TIPS group. No significant differences were observed between the two treatment groups with respect to serious adverse events. In these patients with cirrhosis who were hospitalized for acute variceal bleeding and at high risk for treatment failure, the early use of TIPS was associated with significant reductions in treatment failure and in mortality. (Current Controlled Trials number, ISRCTN58150114.) 2010 Massachusetts Medical Society
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Expansion of Treatment for Hepatitis C Virus Infection by Task Shifting to Community-Based Nonspecialist Providers: A Nonrandomized Clinical Trial.

              Direct-acting antiviral (DAA) therapy for hepatitis C virus (HCV) infection has resulted in high rates of disease cure; however, not enough specialists currently are available to provide care.
                Bookmark

                Author and article information

                Journal
                JAMA Netw Open
                JAMA Netw Open
                JAMA Network Open
                American Medical Association
                2574-3805
                20 July 2023
                July 2023
                20 July 2023
                : 6
                : 7
                : e2324539
                Affiliations
                [1 ]Division of Gastroenterology and Hepatology, Department of Medicine, Indiana University School of Medicine, Indianapolis
                [2 ]Indiana University Simon Comprehensive Cancer Center, Indianapolis
                [3 ]Division of Cardiovascular Medicine, Department of Medicine, Indiana University School of Medicine, Indianapolis
                [4 ]Division of Medicine, University of Minnesota School of Medicine, Minneapolis
                [5 ]Section of Gastroenterology, Department of Medicine, Baylor College of Medicine, Houston, Texas
                [6 ]Michael E. DeBakey Veterans Affairs Medical Center, Houston, Texas
                Author notes
                Article Information
                Accepted for Publication: June 4, 2023.
                Published: July 20, 2023. doi:10.1001/jamanetworkopen.2023.24539
                Open Access: This is an open access article distributed under the terms of the CC-BY License. © 2023 Nephew LD et al. JAMA Network Open.
                Corresponding Authors: Lauren D. Nephew, MD, MSCE ( lnephew@ 123456iu.edu ), and Archita P. Desai, MD ( desaiar@ 123456iu.edu ), Indiana University School of Medicine, 702 Rotary Building, Ste 225, Indianapolis, IN 46202.
                Author Contributions: Drs Nephew and Desai had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.
                Concept and design: Nephew, Mohamed, Orman, Chalasani, Desai.
                Acquisition, analysis, or interpretation of data: Nephew, Knapp, Mohamed, Ghabril, Orman, Patidar, Desai.
                Drafting of the manuscript: Nephew, Mohamed, Desai.
                Critical revision of the manuscript for important intellectual content: Knapp, Ghabril, Orman, Patidar, Chalasani, Desai.
                Statistical analysis: Knapp, Desai.
                Obtained funding: Desai.
                Administrative, technical, or material support: Orman, Desai.
                Supervision: Nephew, Chalasani, Desai.
                Conflict of Interest Disclosures: Dr Chalasani reported receiving personal fees from AbbVie, Madrigal, Zydus, Galectin, Boehringer-Ingelheim, Lilly, and Altimmune; grants from Galectin, Data Safety Monitoring, and Exact Sciences; and owning equity in RestUp. There were no other disclosures reported.
                Funding/Support: Dr Nephew is funded by the National Institute of Minority Health Disparities (award No. K23MD018090-01). Dr Desai is funded by National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health (award No. K23DK123408).
                Role of the Funder/Sponsor: The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
                Data Sharing Statement: See Supplement 2.
                Article
                zoi230721
                10.1001/jamanetworkopen.2023.24539
                10359964
                37471085
                1f50c0ad-4445-435a-9f57-f8dbc8164677
                Copyright 2023 Nephew LD et al. JAMA Network Open.

                This is an open access article distributed under the terms of the CC-BY License.

                History
                : 11 November 2022
                : 4 June 2023
                Categories
                Research
                Original Investigation
                Online Only
                Equity, Diversity, and Inclusion

                Comments

                Comment on this article